The Future
of Itch Relief

The future of itch relief

Numelvi is registered for the treatment of pruritus associated with allergic dermatitis including atopic dermatitis in dogs and for the treatment of inflammation and clinical manifestations of atopic dermatitis in dogs.

Selective

Preferentially targets the JAK1 enzyme, the primary driver of itch and inflammation in allergic dermatitis

Well Tolerated

For dogs and puppies from 6 months old with tablets from 2 kg* in weight

Simple

Easy once-daily dosing from the first dose, to be given at or around mealtimes.

Effective

Significant reduction in itch from 2 hours after the first dose

*A benefit-risk assessment should be made by the responsible veterinarian for dogs less than 3 kg as safety has not been investigated in these dogs.

Skin and Allergic Dermatitis

Skin is the most affected body system in dogs^1,2,3

Skin infections and otitis externa are common in dogs^2,4

Skin is the #2 reason dogs receive veterinary care³

Itch is the most common clinical sign in dogs^4,5,6

Allergic dermatitis^5,6

Atopic dermatitis

Environmental allergens, like house dust mites, mould, plants (pollens) and also food

Food-responsive dermatitis

Proteins like beef, dairy, chicken and wheat

Flea allergy dermatitis

Proteins and other substances in flea saliva

Other

Insect-bite, contact, etc.

Prevalence of allergic dermatitis

Difficult to determine as studies vary in:

Diagnostic and inclusion criteria
Geography
Type of veterinary practice enrolling cases

Prevalence varies due to overlap in clinical signs

^ More than one presumed cause possible

Presumed cause of allergic dermatitis in 289 dogs in a clinical trial

The Science of Selectivity

Cytokines use JAK enzymes to stimulate immune cells.

Cytokines use JAK enzymes to stimulate intracellular signaling pathways.

JAK1 is the primary driver of itch and inflammation.

First-generation JAK inhibitors target the JAK enzymes with little to no selectivity.⁸

High selectivity for JAK1 helps minimize interference with the beneficial functions of other JAKs.

Numelvi is at least 10x more selective for JAK1 over the other JAKs.^†

^† Over the other JAK enzymes in in vitro assays.

Mechanism of Action

Rapidly effective

Significant reduction in itch 2 hours after first dose
For the treatment of pruritus associated with allergic dermatitis including atopic dermatitis in dogs
For the treatment of inflammation and clinical manifestations of atopic dermatitis in dogs

Proven safety and efficacy

At least 10X more selective^† for JAK1, the primary driver of itch and inflammation
High selectivity for JAK1 minimises interference with beneficial functions of other JAKs
Allows adequate response to vaccination when dosed at 3X maximum recommended dose
Well tolerated in dogs from 6 months of age

Simple and convenient

Once daily dosing from day 1
Broadest age and weight range – the only JAK inhibitor for use in dogs from 6 months of age

† Over the other JAK enzymes in in vitro assays.

Find out what the studies say about Numelvi⁷

Compare Numelvi With the Competition

Simple dosing

The average recommended dose is 1.0 mg atinvicitinib per kg body weight orally once daily at or around mealtime.

View Dosage Information

Available in 4 Tablet Strengths for Simple Dosing

Pack images are for illustration purposes

Easy Dosing With Most Dogs Requiring 1 Whole or One-half Tablet

The average recommended dose is 1.0 mg of atinvicitinib per kg body weight orally once daily at or around mealtime.

Simplicity and Convenience

Numelvi makes managing itch seamless.

Simple for Veterinarians

Option for all dogs and puppies from 6 months of age
Easy dosing helps owner compliance

Simple for Dog Owners

Once-daily dosing from the start
Consistent relief with consistent dosing
Reassuring safety profile

Allergic Dermatitis Can Be a Chronic Condition

Some types of allergic dermatitis are chronic, while others can be seasonal. Either way, managing the itch and inflammation with your veterinarian is important.

Finding relief will not only improve your dog’s well-being – but also your own peace of mind.

Significant reduction in itch from 2 Hours after first dose⁹

Once-daily dosing starts relieving itch from day 1 with continued improvement thereafter⁷

^† Over the other JAK enzymes in in vitro assays.

Resources

Access these materials to learn more about allergic dermatitis and how best to care for your itchy dog.

Numelvi overview

EVDC 2025 Symposium – Abstracts & Posters

Numelvi launch offer

Have a question about Numelvi?

Contact an MSD Animal Health Representative

There’s More to Learn About the Future of Itch Relief

Please fill out the form below to request a call from an MSD Animal Health representative and join our Numelvi mailing list.

Name

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Email Address(Required)

Telephone Number(Required)

Region(Required)

Job title

Communications Consent(Required)

I agree to receive information and electronic messages from MSD Animal Health including updates on products provided by MSD Animal Health (please note some material may be promotional in nature)

Schering-Plough Animal Health Ltd (trading as MSD Animal Health) will collect, record and use your name, phone number, postcode and email address (“personal Information”) which you provide to us, for only as long as is necessary for the purposes of contacting you with updates in relation to MSD Animal Health products’ (or similar), (unless we are required or permitted by law to hold the information for a longer period). We may disclose your personal information to organisations who assist us and our affiliated companies (which may be located in other countries including the United States, United Kingdom, Singapore, South America, Poland, China or India). If you would like to know more about our privacy policy, including how to access and seek correction of the personal information MSD holds about you, how to complain about a breach of the New Zealand Privacy Principles, and how MSD handles such complaints, please go to or to https://www.msdprivacy.com/nz/en/index.html , or contact our Privacy Officer at: Level 3, 123 Carlton Gore Road, Newmarket, Auckland, 1023, T 523 6000, msd_privacy_office@msd.com NZ-NUM-251000028

Schering-Plough Animal Health Ltd(trading as MSD Animal Health) will collect, record and use your name, phone number, postcode and email address and other information you provide in this form (“personal Information”), for only as long as is necessary for the purposes of contacting you with updates in relation to MSD Animal Health products’,unless we are required or permitted by law to hold the information for a longer period). We may disclose your personal information to organisations who assist us and our affiliated companies (which may be located in other countries including the United States, United Kingdom, Singapore, South America, Poland, China or India). If you would like to know more about our privacy policy, including how to access and seek correction of the personal information MSD holds about you, how to complain about a breach of the New Zealand Privacy Principles, and how MSD handles such complaints, please go to or to https://www.msdprivacy.com/nz/en/index.html, or contact our Privacy Officer at: Level 3, 123 Carlton Gore Road, Newmarket, Auckland, 1023, T 523 6000, msd_privacy_office@msd.com NZ-NUM-251000028

1. Wiles BM, Llewellyn-Zaidi AM, Evans KM, et al. Canine Genet and Epidemiol. 2017;4:8. 2. O’Neill DG, Church DB, McGreevy PD, et al. PLoS One. 2014;9(3):e90501. 3. Hill PB, Lo A, Eden CAN, et al. Vet Record. 2006;158:533-539 4. Miller J, Simpson A, Bloom P, et al. J Am Anim Hosp Assoc. 2023;59(6):255-284. 5.Hensel P, Santoro D, Favrot C, et al. BMC Vet Res. 2015;11:196. 6. Mueller R. Atopic dermatitis and food-responsive dermatosis. In: Jackson HA, Marsella R, eds. BSAVA Manual of Canine and Feline Dermatology, 4th ed. BSAVA; 2021:76-81. .7. Jirjis et al The Second-generation Janus Kinase 1Selective Inhibitor Atinvicitinib: A Safe and in Dogs with Allergic Dermatitis. Presented at European Veterinary Dermatology Congress; Bilbao, Spain; 11-13 September 2025. 8. Gonzales AJ, Bowman JW, Fici GJ, et al. J Vet Pharmacol Ther. 2014;37(4):317-3. 9. Kowalski et al “The Second-Generation Janus Kinase Inhibitor Atinvicitinib Significantly Reduces Pruritus 2-4 Hours After Dosing Dogs in a Canine Interleukin-31 Model” European Veterinary Dermatology Congress; Bilbao, Spain:11-13 September 2025.

10. Jirjis et al The Second-generation Janus Kinase 1Selective Inhibitor Atinvicitinib: A Safe and in Dogs with Allergic Dermatitis. Presented at European Veterinary Dermatology Congress; Bilbao, Spain; 11-13 September 2025. 11. European Medicines Agency. Numelvi: PUAR – Product Information. 2025. 12. European Medicines Agency. Apoquel: PUAR – Product Information & Assessment Report. 2025.

Numelvi, ACVM No: A012149, is AVAILABLE ONLY UNDER VETERINARY AUTHORISATION

The Future
of Itch Relief